Developer docs
API playgroundTry for free, no card

Search company profiles

Evaro

Full company profile

uuid00029x8

Namestring
Evaro
Legal namestring
Total Access Health Ltd.
Websiteurl
evaro.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Evaro (legal entity: Total Access Health Ltd.) is a UK-based, Norwich-headquartered digital health infrastructure company founded in 2018 by NHS doctors and pharmacists Dr Thuria Wenbar (CEO) and Dr Oskar Wenbar (COO). The company operates an API-first, white-label platform that enables consumer brands, healthcare companies, and digital health platforms to embed regulated clinical services — asynchronous AI-assisted consultations, e-prescribing, pharmacy dispensing, and next-day delivery — directly into their own products under their own brand. Evaro holds the full stack of UK clinical and pharmaceutical licences required to deliver these services at scale, including GPhC pharmacy registration, CQC provider registration, MHRA registered pharmacy status, controlled drugs, specials manufacturing, and wholesale dealer licences, plus ISO 27001 and GDPR compliance and NHS Partner status for services such as oral contraception and Pharmacy First.

Evaro generates revenue through three primary streams: per-prescription transaction fees, recurring B2B platform/licensing fees for white-label and bespoke integration partners, and commission/revenue-share arrangements with pharmacy and delivery partners. Pricing for patient consultations is free at the point of use through partner platforms, while B2B partnership pricing is quote-based and not publicly disclosed. The company distributes exclusively through B2B partnerships, with no direct-to-consumer storefront, and serves a disclosed partner portfolio that includes Clue, Lovehoney, Patchs, e-Surgery, e-Pharmacy, Diabetes Consults, and U-Test Diagnostics across femtech, retail, digital health, online pharmacy, specialty care, and diagnostics.

The platform covers 80+ conditions with 500+ treatments, completes asynchronous consultations in approximately two minutes, delivers medications within 24 hours nationwide across England, Scotland, and Wales, and has cumulatively supported more than 2 million patients. Evaro has raised $26.5M in venture funding to date — a $1.5M seed led by Cornerstone VC and Exceptional Ventures (Jan 2024) and a $25M Series A led by AlbionVC with Simplyhealth Ventures (Jan 2026) — and currently operates with 100–150 employees. The Series A use of funds targets expansion into women's health, men's health, and longevity medicine with a stated goal of 10 million patients within three years.

Short descriptiontext

Evaro is a UK-based, NHS-licensed digital health platform that provides API-first white-label clinical infrastructure — consultations, e-prescribing, dispensing, and delivery — to consumer brands and healthcare companies. It serves 2M+ patients across 80+ conditions through partners including Clue, Lovehoney, and Patchs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNorwich, United Kingdom
HQ citystring
Norwich
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital health platform, embedded healthcare services, online prescription services, white-label telehealth, clinical API infrastructure
Industry2 codes
PRIMARYHLALAIAA
DTC Telehealth with Integrated Online Pharmacy (Cash-Pay/Subscription)
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms
SECONDARYHLALAIAD
ePrescribing & Medication Workflow Platforms (EPCS, formulary, prior auth, med history)
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms
NAICS code3 codes
  • Software Publishers513210
  • Offices of Physicians6211
  • Software Publishers5132
SIC code3 codes
  • Services-Prepackaged Software7372
  • Services-Offices & Clinics Of Doctors Of Medicine8011
  • Retail-Drug Stores And Proprietary Stores5912
Product category
Digital Health Platform
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Prescription Fees
TypeTransaction Fee
Description

Revenue generated from prescription services, likely per-consultation or per-prescription fees charged to patients or passed through from pharmacy fulfillment

2B2B Platform/Licensing Fees
TypeSubscription Recurring
Description

White-label partnership model where healthcare brands and consumer platforms pay for access to Evaro's NHS-licensed clinical infrastructure

3Partner Commissions
TypeAffiliate Referral
Description

Commission or revenue share arrangements with pharmacy partners and delivery services integrated into the platform

Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details3 tiers
1Patient Consultations
ModelFreemiumBilling cadencePay-as-you-go
Notes

Consultation service appears to be free for patients accessing through partner platforms

2Delivery Services
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Royal Mail delivery services: Standard 48hr (2-5 business days) £1.95, Tracked 48hr £3.95, Express 24hr £5.95

3B2B Platform Licensing
ModelSubscriptionBilling cadenceAnnual
Notes

White-label partnership pricing not publicly disclosed - quote-based

GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Evaro operates an API-first digital healthcare platform that enables consumer brands, healthcare companies, and digital health platforms to embed NHS-licensed prescription and consultation services into their own platforms via white-label partnerships. The platform manages the complete prescription lifecycle, including AI-assisted 2-minute online consultations, in-house clinician prescribing, pharmacy dispensing, 24-hour nationwide delivery, and ongoing aftercare across 80+ conditions and 500+ treatments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 2-minute consultation completion time
+4 more records
Product overview1 text field

Evaro operates as a unified digital healthcare platform with an API-first architecture. The core Evaro Platform serves as the foundational infrastructure, supplemented by the e-Surgery sub-brand for direct patient services. The company offers three integration tiers through its Healthcare-as-a-Service model: the forthcoming Self Service Portal (for small businesses), White Label Partnership (full rebrand option), and Platform Integration (bespoke enterprise solution). The platform handles the complete prescription lifecycle from 2-minute AI-assisted consultations through prescribing, pharmacy fulfillment, 24-hour delivery, and ongoing aftercare, supporting over 80 conditions with more than 500 treatments.

Product and service2 records
1Evaro Platform
CategoryCore Platform
Description

API-first digital healthcare platform enabling consumer brands and healthcare companies to embed regulated clinical services including AI-driven consultations, e-prescribing, and pharmacy fulfilment. Supports 80+ conditions with 500+ treatments. Targeted at B2B partners.

2Healthcare-as-a-Service Model
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Period tracking app partnership for NHS contraception services - embedding Evaro's prescription services into Clue's femtech platform to provide contraceptive consultations and prescriptions to users

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Sexual wellness retailer partnership - embedding prescription services into Lovehoney's e-commerce platform for sexual health products and consultations

Strategic tierCoreTypeTechnology or Integration
Description

Digital health platform partnership integrating consultation and prescription services

Strategic tierCoreTypeTechnology or Integration
Description

Online pharmacy partnership providing prescription service integration for digital pharmacy services

5e-Pharmacy
Strategic tierCoreTypeTechnology or Integration
Description

Digital pharmacy partnership for prescription and consultation services integration

Strategic tierCoreTypeTechnology or Integration
Description

Specialty healthcare partnership providing diabetes consultation and prescription pathways

Strategic tierCoreTypeTechnology or Integration
Description

End-to-end diagnostic to prescription pathway partnership - connecting diagnostic testing services with prescription fulfillment through Evaro's platform

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based online doctor and pharmacy service offering asynchronous consultations and prescription fulfilment across a wide range of conditions. Most direct peer to Evaro given overlapping UK DTC telehealth + pharmacy model and comparable regulatory footprint.

2Superdrug Online Doctor
TypeDirect peer
Description

UK high-street retailer's telehealth and online pharmacy platform offering consultation-driven prescriptions. Comparable patient flow, condition range, and pharmacy integration to e-Surgery.

TypeDirect peer
Description

Online consultation and prescription service from one of the UK's largest pharmacy chains. Direct competitor in DTC prescription telehealth with similar treatment catalogue and delivery proposition.

4Boots Online Doctor
TypeBroad incumbent
Description

Boots' online consultation and prescription service covering weight loss, contraception, hair loss and other conditions. Broader incumbent with pharmacy retail footprint but overlapping core telehealth and ePrescribing proposition.

TypeDirect peer
Description

UK GPhC-registered online pharmacy offering asynchronous consultations, ePrescribing, and home delivery across a broad condition set. Direct comparable in scale, regulatory profile, and patient experience.

6Babylon Health (eMed)
TypeBroad incumbent
Description

Originally a UK telehealth pioneer, now part of eMed. Provides asynchronous and synchronous consultations, prescribing, and pharmacy partnerships across multiple conditions. Comparable regulatory and clinical infrastructure but operates at much larger scale.

7Pharmacy2U
TypeDirect peer
Description

Largest NHS-registered online pharmacy in the UK offering NHS and private prescriptions with home delivery. Direct peer in UK online pharmacy and ePrescribing infrastructure, including NHS repeat prescribing.

TypeEmerging player
Description

US-based white-label telehealth and pharmacy infrastructure provider powering D2C health brands. Closest international analogue to Evaro's API-first, embeddable healthcare-as-a-service model for consumer brands.

TypeRegional player
Description

UK healthcare software platform embedded into GP and primary care workflows. Comparable in embedding NHS-licensed infrastructure into partner systems, but focused on clinician-to-patient messaging rather than prescription telehealth.

TypeBroad incumbent
Description

US-listed D2C telehealth and pharmacy platform operating its own consumer brands across weight loss, hair, skin, mental and sexual health. Useful international comparable for Evaro's planned expansion across women's, men's and longevity medicine verticals.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance12 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Evaro

Digital Health Platformevaro.com

Evaro is a UK-based, NHS-licensed digital health platform that provides API-first white-label clinical infrastructure — consultations, e-prescribing, dispensing, and delivery — to consumer brands and healthcare companies. It serves 2M+ patients across 80+ conditions through partners including Clue, Lovehoney, and Patchs.

What Evaro does

Evaro (legal entity: Total Access Health Ltd.) is a UK-based, Norwich-headquartered digital health infrastructure company founded in 2018 by NHS doctors and pharmacists Dr Thuria Wenbar (CEO) and Dr Oskar Wenbar (COO). The company operates an API-first, white-label platform that enables consumer brands, healthcare companies, and digital health platforms to embed regulated clinical services — asynchronous AI-assisted consultations, e-prescribing, pharmacy dispensing, and next-day delivery — directly into their own products under their own brand. Evaro holds the full stack of UK clinical and pharmaceutical licences required to deliver these services at scale, including GPhC pharmacy registration, CQC provider registration, MHRA registered pharmacy status, controlled drugs, specials manufacturing, and wholesale dealer licences, plus ISO 27001 and GDPR compliance and NHS Partner status for services such as oral contraception and Pharmacy First.

Evaro generates revenue through three primary streams: per-prescription transaction fees, recurring B2B platform/licensing fees for white-label and bespoke integration partners, and commission/revenue-share arrangements with pharmacy and delivery partners. Pricing for patient consultations is free at the point of use through partner platforms, while B2B partnership pricing is quote-based and not publicly disclosed. The company distributes exclusively through B2B partnerships, with no direct-to-consumer storefront, and serves a disclosed partner portfolio that includes Clue, Lovehoney, Patchs, e-Surgery, e-Pharmacy, Diabetes Consults, and U-Test Diagnostics across femtech, retail, digital health, online pharmacy, specialty care, and diagnostics.

The platform covers 80+ conditions with 500+ treatments, completes asynchronous consultations in approximately two minutes, delivers medications within 24 hours nationwide across England, Scotland, and Wales, and has cumulatively supported more than 2 million patients. Evaro has raised $26.5M in venture funding to date — a $1.5M seed led by Cornerstone VC and Exceptional Ventures (Jan 2024) and a $25M Series A led by AlbionVC with Simplyhealth Ventures (Jan 2026) — and currently operates with 100–150 employees. The Series A use of funds targets expansion into women's health, men's health, and longevity medicine with a stated goal of 10 million patients within three years.

Evaro firmographics

Firmographics
Name
Evaro
Legal name
Total Access Health Ltd.
Website
https://evaro.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
51–100 employees
Short description
Evaro is a UK-based, NHS-licensed digital health platform that provides API-first white-label clinical infrastructure — consultations, e-prescribing, dispensing, and delivery — to consumer brands and healthcare companies. It serves 2M+ patients across 80+ conditions through partners including Clue, Lovehoney, and Patchs.
Ownership category
akta.pro rank

Evaro industry classification

Industry
Product category
Digital Health Platform
NAICS
Software Publishers (513210), Offices of Physicians (6211), Software Publishers (5132)
SIC
Services-Prepackaged Software (7372), Services-Offices & Clinics Of Doctors Of Medicine (8011), Retail-Drug Stores And Proprietary Stores (5912)
akta.pro industry
PRIMARYHLALAIAA
DTC Telehealth with Integrated Online Pharmacy (Cash-Pay/Subscription)
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms
SECONDARYHLALAIAD
ePrescribing & Medication Workflow Platforms (EPCS, formulary, prior auth, med history)
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms

Keywords

  • Digital health platform
  • Embedded healthcare services
  • Online prescription services
  • White-label telehealth
  • Clinical API infrastructure

Where Evaro is headquartered

Location

Headquarters

HQ city
Norwich
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Evaro business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Prescription Fees: Revenue generated from prescription services, likely per-consultation or per-prescription fees charged to patients or passed through from pharmacy fulfillment
  2. B2B Platform/Licensing Fees: White-label partnership model where healthcare brands and consumer platforms pay for access to Evaro's NHS-licensed clinical infrastructure
  3. Partner Commissions: Commission or revenue share arrangements with pharmacy partners and delivery services integrated into the platform

Pricing tiers

ModelBillingPrice
FreemiumPay-as-you-goPatient Consultations
Unit PricingPay-as-you-goDelivery Services
SubscriptionAnnualB2B Platform Licensing

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Evaro product offering

Product offering

Core offering

Evaro operates an API-first digital healthcare platform that enables consumer brands, healthcare companies, and digital health platforms to embed NHS-licensed prescription and consultation services into their own platforms via white-label partnerships. The platform manages the complete prescription lifecycle, including AI-assisted 2-minute online consultations, in-house clinician prescribing, pharmacy dispensing, 24-hour nationwide delivery, and ongoing aftercare across 80+ conditions and 500+ treatments.

Product overview

Evaro operates as a unified digital healthcare platform with an API-first architecture. The core Evaro Platform serves as the foundational infrastructure, supplemented by the e-Surgery sub-brand for direct patient services. The company offers three integration tiers through its Healthcare-as-a-Service model: the forthcoming Self Service Portal (for small businesses), White Label Partnership (full rebrand option), and Platform Integration (bespoke enterprise solution). The platform handles the complete prescription lifecycle from 2-minute AI-assisted consultations through prescribing, pharmacy fulfillment, 24-hour delivery, and ongoing aftercare, supporting over 80 conditions with more than 500 treatments.

Differentiator

Problem solved

Functional benefit

Products and services

  • Evaro Platform API-first digital healthcare platform enabling consumer brands and healthcare companies to embed regulated clinical services including AI-driven consultations, e-prescribing, and pharmacy fulfilment. Supports 80+ conditions with 500+ treatments. Targeted at B2B partners.
  • Healthcare-as-a-Service Model

Quantifiable outcome

  • 2-minute consultation completion time
  • +4 more outcomes

Companies that use Evaro

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles2 records

Evaro technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability3 records

Feature3 records

Evaro partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered flagship and core.

  • ClueflagshipStrategic or Co-development PartnerPeriod tracking app partnership for NHS contraception services - embedding Evaro's prescription services into Clue's femtech platform to provide contraceptive consultations and prescriptions to users
  • LovehoneyflagshipStrategic or Co-development PartnerSexual wellness retailer partnership - embedding prescription services into Lovehoney's e-commerce platform for sexual health products and consultations
  • PatchscoreTechnology or IntegrationDigital health platform partnership integrating consultation and prescription services
  • e-SurgerycoreTechnology or IntegrationOnline pharmacy partnership providing prescription service integration for digital pharmacy services
  • e-PharmacycoreTechnology or IntegrationDigital pharmacy partnership for prescription and consultation services integration
  • Diabetes ConsultscoreTechnology or IntegrationSpecialty healthcare partnership providing diabetes consultation and prescription pathways
  • U-Test DiagnosticscoreTechnology or IntegrationEnd-to-end diagnostic to prescription pathway partnership - connecting diagnostic testing services with prescription fulfillment through Evaro's platform

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Evaro competitors and assessment

Company assessment

Direct peers

  • Zava: UK-based online doctor and pharmacy service offering asynchronous consultations and prescription fulfilment across a wide range of conditions. Most direct peer to Evaro given overlapping UK DTC telehealth + pharmacy model and comparable regulatory footprint.
  • Superdrug Online Doctor: UK high-street retailer's telehealth and online pharmacy platform offering consultation-driven prescriptions. Comparable patient flow, condition range, and pharmacy integration to e-Surgery.
  • LloydsPharmacy Online Doctor: Online consultation and prescription service from one of the UK's largest pharmacy chains. Direct competitor in DTC prescription telehealth with similar treatment catalogue and delivery proposition.
  • Simple Online Pharmacy: UK GPhC-registered online pharmacy offering asynchronous consultations, ePrescribing, and home delivery across a broad condition set. Direct comparable in scale, regulatory profile, and patient experience.
  • Pharmacy2U: Largest NHS-registered online pharmacy in the UK offering NHS and private prescriptions with home delivery. Direct peer in UK online pharmacy and ePrescribing infrastructure, including NHS repeat prescribing.

Broad incumbents

  • Boots Online Doctor: Boots' online consultation and prescription service covering weight loss, contraception, hair loss and other conditions. Broader incumbent with pharmacy retail footprint but overlapping core telehealth and ePrescribing proposition.
  • Babylon Health (eMed): Originally a UK telehealth pioneer, now part of eMed. Provides asynchronous and synchronous consultations, prescribing, and pharmacy partnerships across multiple conditions. Comparable regulatory and clinical infrastructure but operates at much larger scale.
  • Hims & Hers Health: US-listed D2C telehealth and pharmacy platform operating its own consumer brands across weight loss, hair, skin, mental and sexual health. Useful international comparable for Evaro's planned expansion across women's, men's and longevity medicine verticals.

Emerging players

  • Truepill: US-based white-label telehealth and pharmacy infrastructure provider powering D2C health brands. Closest international analogue to Evaro's API-first, embeddable healthcare-as-a-service model for consumer brands.

Regional players

  • AccuRx: UK healthcare software platform embedded into GP and primary care workflows. Comparable in embedding NHS-licensed infrastructure into partner systems, but focused on clinician-to-patient messaging rather than prescription telehealth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Evaro social profiles

Digital presence

Evaro compliance and trust

Trust signal

Compliance12 records

Evaro financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Evaro leadership team

Management profile

Number of profiles

Profiles5 records

Evaro subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Evaro funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Evaro M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evaro

What does Evaro do?

Evaro operates an API-first digital healthcare platform that enables consumer brands, healthcare companies, and digital health platforms to embed NHS-licensed prescription and consultation services into their own platforms via white-label partnerships. The platform manages the complete prescription lifecycle, including AI-assisted 2-minute online consultations, in-house clinician prescribing, pharmacy dispensing, 24-hour nationwide delivery, and ongoing aftercare across 80+ conditions and 500+ treatments.

Is Evaro a public or private company?

Evaro is a private company. It is classified as venture growth investor backed and is currently operating.

When was Evaro founded?

Evaro was founded in 2018. It employs 51 to 100 people.

Where is Evaro based?

Evaro is headquartered in Norwich, United Kingdom, in the Europe region.

How does Evaro make money?

Three revenue lines are on record. Prescription Fees are the primary driver. The others are B2B Platform/Licensing Fees and partner Commissions.

Who are Evaro's main competitors?

Direct peers on record are Zava, Superdrug Online Doctor, LloydsPharmacy Online Doctor, Simple Online Pharmacy and Pharmacy2U. Broad incumbents are Boots Online Doctor, Babylon Health (eMed) and Hims & Hers Health. Truepill is listed as an emerging player. AccuRx is listed as a regional player.

Does Evaro have an API?

No public API is recorded for Evaro.

What industry is Evaro in?

Evaro's product category is Digital Health Platform. Its primary akta.pro industry code is HLALAIAA, DTC Telehealth with Integrated Online Pharmacy (Cash-Pay/Subscription), with a secondary code of HLALAIAD, ePrescribing & Medication Workflow Platforms (EPCS, formulary, prior auth, med history). Its NAICS code is 513210 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The SaaS NewsEvaro Raises $25M Series AEvaro, a UK-based digital healthcare platform, raised $25M in Series A funding led by AlbionVC. The company serves 2 million patients and aims to reach 10 million users within three years. The funds will expand its healthcare-as-a-service model across consumer brands, healthcare organizations, and employers.Healthcare TodayInnovation in healthcare roundup: Evaro, Ramsay Health Care, Better, VitVioMultiple healthcare organizations in the UK, including Evaro, Ramsay Health Care UK, Better, VitVio, and Scottish Action for Mental Health, have launched innovative services and partnerships to improve access and efficiency in healthcare. These initiatives involve digital health platforms, virtual consultations, AI-powered operational tools, and mental health support centers, with several implementations expanding internationally or across regions.Healthcare TodayEvaro partners with U-Test DiagnosticsNorfolk-based NHS-licensed digital healthcare platform Evaro has partnered with U-Test Diagnostics to become the first UK company offering patients an end-to-end pathway from diagnostic results to prescription and fulfilment. The partnership leverages Evaro's asynchronous consultation model and NHS-licensed prescribing infrastructure to deliver treatments the next day, capitalising on post-pandemic growth in home testing adoption. Evaro recently closed a $25 million Series A funding round led by AlbionVC to scale its healthcare-as-a-service model.Healthcare TodayEvaro closes $25 million Series A fundingNorfolk-based NHS-licensed digital healthcare platform Evaro has closed a $25 million Series A funding round led by AlbionVC, with participation from Simplyhealth Ventures, Exceptional Ventures, Cornerstone VC, and BBI. The funds will be used to scale its healthcare-as-a-service model and expand across treatment areas including women's health, men's health, and longevity medicine. Evaro embeds regulated healthcare services including consultations, diagnostics, prescribing, and aftercare into partner platforms such as Clue and Lovehoney.Pulse 2.0Evaro: $25 Million Series A Raised to Expand Embedded Digital Healthcare For Consumer BrandsEvaro, an NHS licensed digital healthcare platform serving over 2 million patients, has raised a $25 million Series A round led by AlbionVC with participation from Simplyhealth Ventures, Exceptional Ventures, Cornerstone VC, and BBI. The company operates as a healthcare-as-a-service provider, embedding prescription and clinical services into consumer brand platforms such as period tracking app Clue and sexual wellness retailer Lovehoney. Evaro plans to use the funding to expand into women's health, men's health, and longevity medicine while targeting 10 million patients within three years.FinSMEsEvaro Raises $25M in Series A FundingEvaro, a London-based digital health startup, raised $25 million in Series A funding led by AlbionVC with participation from Simplyhealth Ventures, Exceptional Ventures, Cornerstone VC, and BBI. The company operates an API-first platform enabling consumer brands to embed regulated clinical services, including AI-driven consultations, e-prescribing, and pharmacy fulfillment, into their apps. Evaro plans to use the funds to expand operations and business reach.MobiHealthNewsHealthcare integration company Evaro secures $25MEvaro, a healthcare integration company licensed by the NHS, completed a $25 million Series A funding round led by AlbionVC to expand its API and clinical capabilities. The company develops technology to help third-party platforms integrate healthcare services, including consultations, diagnostics, and prescriptions, with current partners like Clue and Lovehoney.Tech.euEvaro secures $25M to support consumer brands in offering digital healthcare servicesEvaro, an NHS-licensed digital healthcare platform, has closed a $25 million Series A funding round led by AlbionVC, with participation from Simplyhealth Ventures, Exceptional Ventures, Cornerstone VC, and BBI. The company provides embeddable prescribing and pharmacy infrastructure that enables consumer brands to offer regulated digital healthcare services across more than 80 conditions and has served over two million patients to date. Looking ahead, Evaro plans to broaden its reach and further develop its healthcare-as-a-service offering in the UK market.EU-StartupsWith Clue and Lovehoney as partners, Evaro secures €21 million to expand NHS-licensed embedded health servicesNorwich-based Evaro, an NHS-licensed digital healthcare platform serving over 2 million patients, has closed a €21 million Series A funding round led by AlbionVC, with participation from Simplyhealth Ventures, Exceptional Ventures, Cornerstone VC, and BBI, to expand across women's health, men's health, and longevity medicine treatment areas, as well as clinical diagnostics and platform development. The platform partners with period-tracking app Clue and sexual wellness retailer Lovehoney, embedding prescription services directly into their customer experiences, and aims to serve 10 million patients over the next three years as part of establishing healthcare-as-a-service as a new market category.BusinessCloudEvaro bags £18m ‘to turn any brand into digital healthcare provider’Evaro, an NHS-licensed digital healthcare platform serving over two million patients, has closed a Series A funding round of approximately £18 million. The Norwich-based firm will use the funding to accelerate its healthcare-as-a-service model, enabling consumer brands to embed regulated healthcare services into their platforms within weeks. The round was led by AlbionVC with participation from Simplyhealth Ventures, Exceptional Ventures, Cornerstone VC, and BBI, and comes amid 20.5 million people experiencing month-long GP waits in 2024.